January 2017 - Cancer Currents Blog
-
Less-Frequent Zoledronic Acid Treatment Effective at Preventing Bone Metastasis ComplicationsIn a clinical trial involving patients with metastatic cancer, administration of zoledronic acid every 12 weeks was as effective at preventing skeletal-related events caused by bone metastases as administration every 4 weeks.
-
Genome Study Points to New Subtypes of Esophageal CancerA new study by The Cancer Genome Atlas Research Network could help classify esophageal cancers according to their genetic and molecular alterations and identify potential new treatment options.
-
Shifts Seen in Tobacco Product Types Purchased in USThe consumption of cigarettes, small cigars, and chewing tobacco has declined over the past 15 years, according to a new study. These declines were partially offset by a rise in consumption of large cigars, pipe tobacco, and snuff.
-
The Global Economic Burden of Tobacco: An Interview with Dr. Mark ParascandolaNCI’s Dr. Mark Parascandola answers questions about The Economics of Tobacco and Tobacco Control, the latest in a series of monographs on tobacco use and tobacco control, which was co-written with the World Health Organization.
-
Ibrutinib Relieves Chronic Graft-Versus-Host Disease SymptomsThe targeted cancer therapy ibrutinib can effectively treat the symptoms of chronic graft-versus-host disease, a common and serious complication of allogeneic stem cell transplants, findings from a small clinical trial show.
-
FDA Approves Rucaparib for BRCA-Positive Ovarian CancerThe FDA has approved rucaparib for women with BRCA-positive advanced ovarian cancer based on findings from two small clinical trials showing that it shrank tumors.
-
For Some Breast Cancer Survivors, Drug May Reduce Treatment-Related Joint PainResearchers have found that duloxetine (Cymbalta®), a drug most commonly used to treat depression, may also reduce joint pain caused by aromatase inhibitors in some women being treated for early-stage breast cancer.